Search Within

Walid Khaled Chatila

  1. "Body Imaging Service"
Formats
  1. Journal Article (6)
  2. Meeting Abstract (4)
Groups
  1. Body Imaging Service (10)
  2. Center for Molecular Imaging and Biotechnology (CMIB) (10)
  3. Computational Oncology Service (10)
  4. Department of Medicine (10)
  5. Epidemiology and Biostatistics (10)
  6. GSK Faculty (10)

More Groups

People
  1. Nikolaus Schultz (10)
  2. David Solit (7)
  3. Henry Walch (5)
  4. Joanne Chou (5)
  5. Kinh Gian Do (5)
  6. Marinela Capanu (5)

More People

Years
  1. 2025 (1)
  2. 2024 (1)
  3. 2023 (1)
  4. 2022 (1)
  5. 2021 (1)
  6. 2020 (3)

More Years

Publications
  1. Journal of Clinical Oncology (5)
  2. Annals of Surgical Oncology (1)
  3. Clinical Cancer Research (1)
  4. Clinical Colorectal Cancer (1)
  5. Lancet Oncology (1)
  6. The Oncologist (1)
Publishers
  1. American Society of Clinical Oncology (5)
  2. American Association for Cancer Research (1)
  3. Elsevier Inc. (1)
  4. Elsevier Science, Inc. (1)
  5. Oxford University Press (1)
  6. Springer (1)

Results (10)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecular and clinical determinants of targeted therapy (TT) outcomes in biliary tract cancer (BTC): Analysis of a prospectively maintained next generation sequencing (NGS) biorepository
    Meeting Abstract

    Cowzer, D.; Walch, H. S.; Atri, P.; Shah, F.; Huq, R.; Khalil, D. N.; Park, W.; Yeh, R.; Do, R. K. G.; Basturk, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Clinicogenomic predictors of outcomes in patients with hepatocellular carcinoma treated with immunotherapy
    Journal Article

    Cowzer, D.; Chou, J. F.; Walch, H.; Keane, F.; Khalil, D.; Shia, J.; Do, R. K. G.; Yarmohammadi, H.; Erinjeri, J. P.; El Dika, I.; more...
    The Oncologist (2024)

    Fulltext@MSK | Save
  • Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer
    Journal Article

    Maron, S. B.; Chatila, W.; Walch, H.; Chou, J. F.; Ceglia, N.; Ptashkin, R.; Do, R. K. G.; Paroder, V.; Pandit-Taskar, N.; Lewis, J. S.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Local therapy for oligoprogression or consolidation in high mutational burden stage 4 colorectal cancer treated with PD-1 or PD-L1 blockade
    Journal Article

    Klemen, N. D.; Court, C. M.; Fernandes, M. C.; Walch, H. S.; Chatila, W. K.; Saadat, L. V.; Maron, S.; Crane, C.; Shia, J.; Cercek, A.; more...
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Walch, H. S.; Ptashkin, R.; Sabwa, S.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Systemic chemotherapy for metastatic colitis-associated cancer has a worse outcome than sporadic colorectal cancer: Matched case cohort analysis
    Journal Article

    Yaeger, R.; Paroder, V.; Bates, D. D. B.; Capanu, M.; Chou, J.; Tang, L.; Chatila, W.; Schultz, N.; Hersch, J.; Kelsen, D.
    Clinical Colorectal Cancer (2020)

    Fulltext@MSK | Save
  • Pembrolizumab with trastuzumab and chemotherapy (PTC) in HER2-positive metastatic esophagogastric cancer (mEG): Plasma and tumor-based biomarker analysis
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Millang, B. M.; Sabwa, S.; Chou, J. F.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: An open-label, single-arm, phase 2 trial
    Journal Article

    Janjigian, Y. Y.; Maron, S. B.; Chatila, W. K.; Millang, B.; Chavan, S. S.; Alterman, C.; Chou, J. F.; Segal, M. F.; Simmons, M. Z.; Momtaz, P.; more...
    Lancet Oncology (2020)

    Fulltext@MSK | Save
  • Clinical and molecular features predicting long-term response (LTR) to anti-PD-(L)1 based therapy in patients with NSCLC
    Meeting Abstract

    Rizvi, H.; Plodkowski, A. J.; Tenet, M.; Halpenny, D.; Long, N.; Sauter, J. L.; Sanchez-Vega, F.; Chatila, W. K.; Schultz, N.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing
    Journal Article

    Rizvi, H.; Sanchez-Vega, F.; La, K.; Chatila, W.; Jonsson, P.; Halpenny, D.; Plodkowski, A.; Long, N.; Sauter, J. L.; Rekhtman, N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save